Benefit of surgery for ductal carcinoma in-situ investigated

Breast surgery performed at or shortly after a diagnosis of low-grade ductal carcinoma in-situ (DCIS) did not significantly change patients' survival rate. The survival rate for those with intermediate- and high-grade DCIS does improve with surgery, but the work raises concerns about overtreatment and the necessity and benefit of surgery for all patients with low-grade DCIS. This study was published in JAMA Surgery (2015; doi:10.1001/jamasurg.2015.0876).

"Until now, the benefit of surgical management for DCIS had not been investigated; we didn't know the impact of such surgery for this very early breast cancer. By using registry data, we could estimate the benefit," said corresponding author Yasuaki Sangara, MD, of the Department of Surgery at Brigham and Women's Hospital and Dana Farber/Brigham and Women's Cancer Center in Boston, Massachusetts. "Among patients with high- and intermediate-grade DCIS, we do see a statistical difference between the surgery and nonsurgery groups, but that significant benefit was not observed for patients with low-grade DCIS."

DCIS is a cancer of the milk ducts and is the most common type of noninvasive breast cancer. Improvements in early detection have dramatically increased the number of cases of DCIS; the disease is diagnosed in approximately 60,000 women each year, accounting for 20% to 25% of new breast cancer cases in the United States.

An estimated 25% to 50% of DCIS cases may progress to invasive ductal carcinoma. This rate varies depending on whether a woman's DCIS is categorized as low-, intermediate- or high-grade, but the standard of care for all grades is surgery.

"We are over treating breast cancer in the United States and this study, along with others, suggests the need for treatment strategies tailored to a woman's specific cancer, not just breast cancer in general," said senior author Mehra Golshan, MD, director of Breast Surgical Services at Dana-Farber/Brigham and Women's Cancer Center. Golshan is also director of Breast Surgical Services at the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute.

The team looked at data from more than 50,000 cases of DCIS available from the Surveillance, Epidemiology and End Results (SEER) database collected between 1998 and 2011 at the Dana-Farber/Brigham and Women's Cancer Center.

For low-grade DCIS, the 10-year survival rate for women who did not receive surgery at or shortly after diagnosis was 98.8%, and the survival rate for women who did receive surgery was 98.6%. For women with intermediate- or high-grade DCIS, the survival rate was significantly different between those who had surgery and those who did not.

"This study alone does not allow us to definitively conclude that breast surgery should be avoided for women with low-grade DCIS, but we believe that a prospective clinical trial, following patients over time from diagnosis through treatment and beyond, is warranted," said Sagara.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs